Congress Presentations
Stay informed about the latest scientific and medical research from Axsome.
Psych Congress 2025: Poster Reception
San Diego, CA | September 20, 2025
AXS-05 | Major Depressive Disorder
Efficacy, Tolerability, and Safety of Dextromethorphan-Bupropion (45mg/105mg), a Novel Oral Antidepressant: Data from 3 Clinical Trials
AXS-05 | Major Depressive Disorder
Initiating Dextromethorphan-Bupropion (45mg/105mg) in Patients With Major Depressive Disorder (MDD): Expert Panel Consensus Recommendations
AXS-05 | Major Depressive Disorder
Supplemental Information for “Initiating Dextromethorphan-Bupropion (45mg/105mg) in Patients With Major Depressive Disorder (MDD): Expert Panel Consensus Recommendations” – All Recommendations
AXS-05 | Major Depressive Disorder
Dextromethorphan-Bupropion (45mg/105mg) in Major Depressive Disorder: Pooled Data from Two Six-Week Controlled Trials (GEMINI and ASCEND)
AXS-05 | Major Depressive Disorder
Impact of Dextromethorphan-Bupropion (45mg/105mg) on Patient-Reported Insomnia Symptoms: Results From the GEMINI Trial
AXS-05 | Major Depressive Disorder
Effects of Dextromethorphan-Bupropion (45mg/105mg) in Improving Anhedonia and Interest-Activity Symptoms of Major Depressive Disorder and the Associated Improvements in Functional Impairment
AXS-05 | Major Depressive Disorder
Real-World Dextromethorphan-Bupropion (45mg/105mg) Patient Characteristics in Major Depressive Disorder
AXS-05 | Alzheimer’s Disease Agitation
Efficacy and Safety of AXS-05 in Alzheimer’s Disease Agitation: Results From ACCORD-1, a Phase-3, Double-Blind, Placebo-Controlled, Relapse Prevention Study
AXS-05 | Alzheimer’s Disease Agitation
Efficacy and Safety of AXS-05 in Alzheimer's Disease Agitation: Results From ACCORD-2, a Phase 3 Randomized Withdrawal Double-Blind Placebo-Controlled Study
AXS-12 | Narcolepsy
Impact of AXS-12 on Symptom Severity and Functional Impairment in Narcolepsy: Results from the Phase 3 SYMPHONY Trial
AXS-12 | Narcolepsy
ENCORE: Topline Results of a Phase 3 Open-Label Extension and Randomized-Withdrawal Trial of AXS-12 in Narcolepsy
AXS-12 | Narcolepsy
Residual Symptom Burden in Patients With Narcolepsy Satisfied With Treatment: Subgroup Analysis From The CRESCENDO Survey
Solriamfetol | Excessive Daytime Sleepiness
Effects of Solriamfetol on Neuropsychological Outcomes in Patients with Obstructive Sleep Apnea in the Real-World SURWEY Study
Solriamfetol | Excessive Daytime Sleepiness
Effects of Solriamfetol on Neuropsychological Outcomes in Patients with Narcolepsy in the Real-World SURWEY Study
